Artiva Biotherapeutics, Inc. has disclosed a stock transaction involving its Chief Technical Operations Officer, Christopher Horan. The filing indicates that Horan sold 20,546 shares of the company's common stock on November 17, 2026. This transaction is significant as it highlights ongoing changes in management and the company's approach to stock ownership.
Artiva Biotherapeutics, based in San Diego, specializes in the development of biological products, specifically in the field of immunotherapy. The company operates under the SIC code 2836, which is designated for Biological Products, (No Diagnostic Substances). Artiva is an emerging growth company listed on the Nasdaq under the ticker symbol ARTV.
According to the SEC filing, the shares were sold at a price of $3.9119 each. The filing also notes that the sale was part of a 'sell-to-cover' policy, which allows executives to sell shares to cover tax withholding obligations associated with the vesting of restricted stock units. Following this transaction, Horan retains ownership of 281,775 shares.
This development may affect investor confidence in Artiva's leadership, as stock transactions by executives can signal various strategic decisions. The biological products industry is characterized by rapid changes, and the actions of key personnel often reflect broader trends within the sector.
The filing does not specify what actions will follow this transaction, leaving stakeholders to speculate on future developments regarding Artiva's management and strategic direction.
Read Next
Clark Kyle Sells 15,000 Shares of Beta Technologies Stock
Ronald R. Taylor resigns as director of ResMed Inc.
Afsari Nasym acquires 68,235 shares of Onterris, Inc.
Onterris, Inc. Chief Strategy Officer Acquires Shares
StubHub Holdings' Mark Streams Sells 76,891 Shares
Francesca M. Edwardson Transfers 25,000 Shares to Trust




